ClinicalTrials.Veeva

Menu
T

The Crofoot Research Center, Inc. | Houston, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Islatravir
Lenacapavir
Doravirine
Bictegravir
Emtricitabine
Tenofovir Alafenamide
ISL
TAF
DOR
ABBV-382

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

15 of 32 total trials

A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)

The purpose of this study is to evaluate the safety and tolerability of DOR/ISL in adult participants with HIV-1 who had been previously treated with...

Active, not recruiting
HIV Infection
Drug: DOR/ISL

The goal of this study is to test the effectiveness, safety, and tolerability of the combination of broadly neutralizing antibodies (bNAbs) (teropavi...

Active, not recruiting
HIV Infections
Drug: Lenacapavir Tablet
Drug: Zinlirvimab

Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV disease is considered to be a chronic di...

Active, not recruiting
Human Immuno-deficiency Virus (HIV) Disease
Drug: Placebo for Budigalimab
Drug: Budigalimab

The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in t...

Enrolling
COVID-19 SARS-CoV-2 Infection
Drug: placebo
Drug: ibuzatrelvir

The primary objectives of this study are to evaluate the safety and tolerability of a switch to Doravirine/Islatravir (DOR/ISL) compared with continu...

Active, not recruiting
HIV-1 Infection
Drug: DOR/ISL
Drug: ART

The primary objectives of this study are to evaluate the antiretroviral activity of a switch to Doravirine/Islatravir (DOR/ISL) compared with continu...

Active, not recruiting
HIV-1 Infection
Drug: BIC/FTC/TAF
Drug: DOR/ISL

The safety and tolerability of MK-8591A, a 2-drug fixed dose combination (FDC) of doravirine (DOR 100mg) and islatravir (ISL 0.75mg) will be evaluate...

Active, not recruiting
HIV-1 Infection
Drug: MK-8591A

The primary objective of this study is to evaluate the efficacy of oral weekly islatravir (ISL) in combination with lenacapavir (LEN) in virologicall...

Active, not recruiting
HIV-1 Infection
Drug: B/F/TAF
Drug: ISL

The goal of this clinical study is to test how well the study drug, lenacapavir (LEN), works in preventing the risk of HIV.

Active, not recruiting
Pre-Exposure Prophylaxis of HIV Infection
Drug: PTM F/TDF
Drug: Placebo SC LEN
Status recently updated

The goal of this clinical study is to learn more about the study drug, obeldesivir (ODV; GS-5245), and how safe and effective it is in treating nonho...

Enrolling
Active, not recruiting
RSV Infection
Drug: Obeldesivir
Drug: Obeldesivir Placebo

The goal of this clinical study is to learn more about the experimental drugs GS-1720 and GS-4182; to compare the combination of GS-1720 and GS-4182...

Active, not recruiting
HIV-1-Infection
Drug: Placebo to Match BVY
Drug: Placebo to Match GS1720/GS-4182 FDC

The goal of this clinical study is to learn about the safety and efficacy of switching to once weekly tablet of islatravir/lenacapavir (ISL/LEN) regi...

Enrolling
HIV-1-infection
Drug: B/F/TAF
Drug: PTM ISL/LEN

The goal of this clinical study is to learn more about the safety and efficacy of switching to a once weekly tablet of islatravir/lenacapavir (ISL/LE...

Active, not recruiting
HIV-1-Infection
Drug: Antiretroviral Combinations
Drug: ISL/LEN

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC)/lenacapavir (LEN), fixed-dose c...

Active, not recruiting
HIV-1-infection
Drug: B/F/TAF
Drug: Placebo to match B/F/TAF

The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing re...

Active, not recruiting
HIV-1-infection
Drug: Optimized Background Regimen (OBR)
Drug: Oral Lenacapavir Placebo

Trial sponsors

Gilead Sciences logo
Merck Sharp & Dohme (MSD) logo
AbbVie logo
C
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems